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There is evidence of the reciprocal influence between the alteration of circadian rhythms
and Substance Use Disorders (SUD), and part of the success of the SUD treatment lays
in the patient’s rhythmic recovery. We aim to elucidate the effect of the SUD treatment
in circadian rhythmicity considering, for the first time, the age of onset of substance
use (OSU) and duration of abstinence. We registered the sleep-wake schedules, the
chronotype and the distal skin temperature of 114 SUD patients with at least 3 months
of abstinence, considering whether they had begun consumption at age 16 or earlier
(OSU ≤ 16, n = 56) or at 17 or later (OSU ≥ 17, n = 58), and duration of abstinence
as short (SA: 3 to 5 months, n = 38), medium (MA: 6 to 9 months, n = 35) or long
(LA: more than 9 months, n = 41). Moreover, we compared the patients’ distal skin
temperature pattern with a similar sample of healthy controls (HC, n= 103). SUD patients
showed amorningness tendency and higher night values, amplitude and stability, a better
adjustment to the cosine model and lower minimum temperature and circadianity index
in the distal skin temperature rhythm, in contrast to the HC group. The OSU ≥ 17 and
LA groups showed a more robust distal skin temperature pattern, as well as milder
clinical characteristics when compared to the OSU ≤ 16 and SA groups, respectively.
The circadian disturbances associated to substance consumption seem to improve with
treatment, although the age of OSU and the duration of abstinence are modulating
variables. Our results highlight the need to include chronobiological strategies that
boost circadian rhythmicity both in SUD prevention and rehabilitation programs. The
measurement of distal skin temperature rhythm, a simple and reliable procedure, could
be considered an indicator of response to treatment in SUD patients.
Keywords: abstinence, circadian rhythm, chronotype, distal skin temperature, onset of substance use, sleep-wake
schedules, substance use disorder
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INTRODUCTION
During adolescence there is a higher risk to begin substance
consumption (1, 2), and an early age of onset of substance use
(OSU) is associated to the future development of Substance Use
Disorders (SUD) (3) and to more severe clinical characteristics
(4–8). Therefore, it is crucial to improve substance consumption
prevention programs, as well as to consider the age of OSU and its
clinical implications in SUD treatments. Chronobiology is here
an area of high interest thanks to the evidence collected in the
last decades.
Biological rhythms are essential to survival, and their
alteration has been consistently linked to a wide range of
health problems (9, 10), including SUD. Circadian rhythms
(lasting around 24 h) deserve special attention given their
relevance in both work and clinical performance. They are
endogenously generated by the body’s biological clock, located
in the suprachiasmatic nucleus of the hypothalamus, although
they are synchronized with the environmental rhythm of light-
darkness (11, 12). Several functions, both physiological (body
temperature, hormone secretion, wake-sleep cycle, etc.) and
psychological (mood, cognitive performance, etc.), show an
evident circadian rhythmicity (10, 13–15).
Some parameters, such as body temperature or melatonin
secretion, are considered biological markers of circadian
rhythmicity (16, 17). In recent years, there is a growing interest
to measure distal skin temperature, since it is easy to record
and reflects internal temporal order reliably (18–21). Distal skin
temperature has been validated for sleep-wake detection (22),
and it can be used instead of dim-light melatonin onset to
predict the internal phase (21), since it remains after demasking
procedures (20). Its usefulness has been proven in very different
populations, among others, babies, and older people (23), mild
cognitive impairment (24), sleep-disordered breathing (25), or in
patients with metabolic syndrome (26).
Different studies show that substance consumption alters the
expression of circadian rhythmicity, and this can last for months
after the onset of abstinence (27, 28).
The most frequent alterations are a decrease in the amplitude
and a phase delay in circadian functions, seen both in body
temperature and in melatonin secretion (29–31). In this regard,
the genes regulating the circadian system seem to be involved
in the activity of the reward system in response to substance
use (32–34), and it is suggested that alterations in its activity
Abbreviations: CGI, Clinical Global Impression questionnaire; CSM, Composite
Scale of Morningness; DAST-20, Drug Abuse Screening Test; DSM-IV-TR,
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revised;
HC, healthy controls; IS, interdaily stability; IV, intradaily variability; L10,
minimum mean temperature in 10 consecutive hours; L2, minimum mean
temperature in 2 consecutive hours; LA, long abstinence; M5, maximum mean
temperature in 5 consecutive hours; MA, medium abstinence; OSU≤16, age of
onset of substance use at age 16 or earlier; OSU≥17, age of onset of substance
use at age 17 or later (OSU≥17); RA, relative amplitude; SA, short abstinence;
SCID-I, Structural Clinical Interview for the DSM-IV Axis I Disorders; SPAQ,
Seasonal Pattern Assessment Questionnaire; SUD, Substance Use Disorder; TL10,
time when the minimum temperature in 10 consecutive hours was reached; TL2,
time when the minimum temperature in 2 consecutive hours was reached; TM5,
time when the maximum mean temperature in 5 consecutive hours was reached;
%V, percentage of variance explained by the cosine wave.
contribute to the vulnerability of developing a SUD (34–36).
Moreover, substance consumption may modify the genetic
expression with more or less permanent changes, depending on
the severity of consumption and the subject’s vulnerability (37).
Individuals show circadian rhythm differences depending on
their chronotype or circadian typology (morning-, neither-, and
evening-type). This is an individual difference, usually assessed
with self-informed questionnaires (38), and which several recent
studies have shown to be a crucial health variable. Thus, the
evening chronotype is considered a risk factor for substance
consumption both for youth and adults (36, 39, 40). This has been
linked to obtaining a higher reinforcement with consumption
(37, 41, 42), and with a greater social jet-lag or desynchronization
between the biological and the social clocks (43, 44). Moreover,
evening-type subjects show more personality traits associated to
substance use (45, 46), worse academic and work adjustment
(40, 47), less ability to cope with stress (48), and worse quality
of life (49).
Several studies have highlighted the importance of the age of
onset of substance use on the consequences of those who develop
a SUD. When compared to people who begin consumption at 17
or later, those who begin at 16 or earlier have a lower premorbid
intelligence quotient (7, 50), a worse neuropsychological
performance (51, 52), maladaptive treatment-coping strategies
(8), and a lesser volume of gray brain matter (53). This cut-off age
has been based on neurodevelopmental characteristics, such as a
possible dysfunction in the dopaminergic and endocannabinoid
systems. These systems are key to prefrontal function, have a
final peak of cortical changes at about age 15, and are almost
completely defined toward the end of puberty (36, 54). Bearing
in mind that dopamine has been established as a modulator
of the circadian system (36, 55), it is necessary to explore the
possible rhythmic differences in SUD patients considering this
cut-off age of onset of consumption. SUD treatment requires an
integral, long-lasting approach, where the first year of treatment
is considered as a phase of early remission (56), where it is useful
to prescribe sleep schedules and stable, morning-type activities
to patients. However, we are not aware of any previous studies
addressing the influence of age of onset of consumption and
duration of abstinence in the rhythmic circadian expression of
SUD patients undergoing treatment.
Our work has two aims. The first is to examine the differences
in the clinical characteristics of male patients under treatment
for SUD, and after the detox phase, depending on whether they
initiated substance use at age 16 or earlier (OSU ≤ 16) or at
age 17 or later (OSU ≥ 17), and the duration of abstinence
(short, medium or long). The second is to explore the differences
in the circadian rhythmicity of distal skin temperature in SUD
patients, according to the age of OSU and duration of abstinence,
compared with a similar sample of healthy controls. We also
measure circadian typology and sleep-wake schedules for SUD
patients.
MATERIALS AND METHODS
Study Design and Participants
In a cross-sectional study design, participants were recruited
from March 2014 to July 2017. A total of 156 patients were
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referred to our study by their treating psychiatrist or psychologist.
All of them were under SUD treatment in specialized healthcare
resources (ambulatory or residential in a therapeutic community)
from Barcelona. Forty-one patients were excluded due to refuse
to participate in the study or dropout of it (n = 11), psychiatric
comorbidity (n = 2), drug relapse (n = 5), treatment dropout
(n = 8), refuse temperature monitoring (n = 6), or invalid
temperature recording (n = 9). Thus, 114 participants satisfied
our inclusion/exclusion criteria and SUD disorder with cocaine,
alcohol, cannabis or opioids as primary drug of dependence.
The inclusion criteria were: (a) aged 18–55; (b) current or past
diagnosis of SUD according to the criteria in the Diagnostic
and Statistical Manual of Mental Disorders, 4thEdition Text
Revised (DSM-IV-TR) (57); and (c) in abstinence for at least
3 months (excluding caffeine or nicotine consumption), to
ensure the overcoming of withdrawal symptoms and minimum
adherence to treatment, confirmed by urinalysis. The exclusion
criteria were: (a) presence of any other medical problems which
could interfere in the assessment (such as sensorial deficits or
neurological injury); and (b) presence of a comorbid axis I mental
disorder confirmed by a diagnostic interview according to DSM-
IV-TR criteria. All patients were male, given the high prevalence
of this gender in SUD (2) and to avoid bias on the results due to
sex differences (23, 41). After collecting the data, patients were
assigned to groups according to the age of OSU and the duration
of abstinence. To study the effect of the age of OSU, they were
assigned to two groups: age of OSU at 16 or earlier (OSU ≤ 16;
n = 56), or at 17 or later (OSU ≥ 17; n = 58). The groups based
on duration of abstinence were for short abstinence (SA; n= 38)
from 3 to 5 months, for medium abstinence (MA; n = 35) from
6 to 9 months, and for long abstinence (LA; n = 41) when more
than 9 months.
Healthy controls volunteers (HC; n = 103) were recruited
from the community of Murcia and Barcelona with exclusion
criteria similar than those in the SUD groups, with the added
requirement that they must not present any current or past
DSM-IV-TR (57) diagnosis.
This study was approved by the ethics committees of the
University of Barcelona for the SUD and HC participants, and
also by the University of Murcia in the case of the HC. The
study was conducted in accordance with the ethical principles
of the declaration of Helsinki (58) and the international ethical
standards of chronobiological research (59). Study participants
provided written informed consent for participation and were
not compensated.
Sociodemographic and Clinical Measures
Sociodemographic data (age, years of education, marital, and
economic status) and clinical (presence of substance use
and psychiatric pathology in family history, suicidal attempts,
consumption pattern, type of drugs used, age of OSU, duration
of drug use, type of treatment, current medication, abstinence
period, past treatment for SUD, previous relapses, and number
of daily cigarettes and caffeine beverages) were collected by
means of a structured interview designed specifically for our
study, and the Structural Clinical Interview for the DSM-IV
Axis I Disorders (SCID-I) (60). This information was confirmed
through the patients’ treating psychiatrist and themedical history
of the centers’ databases.
The Clinical Global Impression questionnaire (CGI) (61)
was applied as a subjective measure of clinical severity. The
Spanish version (62) of the Drug Abuse Screening Test (DAST-
20) (63) was administered to assess the severity of the SUD.
This test provides a total score from 0 to 20 (0 indicating no
addiction, 1–5 low, 6–10 intermediate, 11–15 substantial, and
16–20 severe). Furthermore, the Seasonal Pattern Assessment
Questionnaire (SPAQ) (64) in its Spanish version (65) was used to
assess seasonality of mood variations. The SPAQ assigns a Global
Seasonality Score (GSS) determined by responses to six indices of
seasonality (sleep length, mood, social activity, weight, appetite,
and energy level) ranging from 0 to 24, and also considers
the degree in which seasonal changes are a problem (no,
mild, moderate, marked, severe, or disabling). Three categories
are established: no seasonal affective disorder [GSS < 10],
subsyndrome of seasonal affective disorder [9 < GSS < 12 and
seasonal variations being perceived as a problem, or GSS> 11 but
seasonal changes being of minor degree], and seasonal affective
disorder [GSS> 11 and seasonal variations consideredminimum
as a moderate problem].
Circadian Typology and Sleep-Wake Data
The Composite Scale of Morningness (CSM) (66) in its Spanish
version (67) was administered to SUD patients as a measure
of circadian typology. This test is composed of 13 items with
Likert-scale answers, with a total score from 13 to 55. In the
Spanish version, the scores for the circadian typologies were 13–
25 for the evening-type, 26–36 for the neither-type, and 37–55 for
the morning-type. We also collected sleep-wake data through a
structured interview designed specifically for our study: total time
spent sleeping, wake-up time, bedtime, presence and duration
of nap.
Distal Skin Temperature Measurement
Distal skin temperature was registered every 10min for 48 h
using the Thermochron iButton R© DS1921H device (Maxim
Integrated Products, Sunnyvale, California, USA), which had an
accuracy of±1◦C at 0.125◦C (19). In order to reduce the potential
masking effect generated by the higher activity of the dominant
hand, the sensor was placed on the wrist of the non-dominant
hand over the radial artery (18). Participants were encouraged to
maintain their usual lifestyles during temperature measurements.
Statistical Analyses
The temperature data were analyzed through the
CircadianwareTM version 7.1.1 software (68). The Cosinor
analyses (parametric) were applied to calculate the maximum
and minimum temperature, mesor, amplitude, acrophase,
Rayleigh vector, and percentage of variance explained by the
cosine wave (%V), as well as the Fourier analysis with the
first 12 harmonics. Furthermore, the circadianity index was
calculated in a similar way to that described in Batinga et al.
(23). A nonparametric analysis was also performed, as previously
described by Witting et al. (69) and Martinez-Nicolas et al. (70),
that provided the interdaily stability (IS), intradaily variability
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(IV), relative amplitude (RA), maximum mean temperature
in 5 consecutive hours (M5) and its respective timing (TM5),
minimum mean temperature in 2 consecutive hours (L2) and
its timing (TL2), minimum mean temperature in 10 consecutive
hours (L10) and its timing (TL10). Furthermore, the mean
temperature values of four main phases according to local time
were calculated, as explained in Batinga et al. (23): morning
decrease (08:00–15:00 h), afternoon secondary peak (15:00–
18:00 h), evening decrease (18:00–23:00 h), and night plateau
(23:00–08:00 h).
Descriptive statistics and frequencies were calculated for
all groups considered. Differences between groups in the
sociodemographic and clinical variables were explored with
the Mann-Whitney U test (U) or with the Chi Square test
(χ2) for categorical variables. If the quantitative data fulfilled
the necessary conditions, the Student’s t-test (t) or the one-
way analysis of variance (ANOVA) were used. Otherwise, the
non-parametric Mann-Whitney U-test (U) or the Kruskal-
Wallis test were used instead. The internal consistency for
the CSM was calculated with the Cronbach’s alpha coefficient.
Differences in CSM scores were assessed using analysis of
covariance (ANCOVA), while the sleep-wake schedules, distal
skin temperature parametric (cosinor) and non-parametric data
were assessed with three multivariate analyses of covariance
(MANCOVA). Age was considered as covariate in all cases,
since it could be a confounding factor. These comparisons were
performed first attending to the diagnostic (HC or SUD groups),
second considering the HC and the age of OSU (OSU ≤ 16 or
OSU ≥ 17) groups, and third attending to the HC and duration
of abstinence (SA, MA, or LA) groups, except for the sleep-wake
schedules and CSM, since no data were recorded for the HC
participants. Additional analyses were performed considering the
type of treatment (residential or ambulatory), to assess whether
this was an indicator of differences in some circadian measure.
The Bonferroni’s test was applied in all analyses to reduce the
occurrence of a type I error. The effect size was calculated with
the partial Eta squared (η2p), assuming a value of 0.01 as low, of
0.06 as moderate and of 0.14 as high (71). Statistical analyses were
performed using the Statistical Package for the Social Sciences
(SPSS; version 22.0), considering bilateral statistical significance
with an established type I error at 5% (p< 0.05).
RESULTS
Sociodemographic and Clinical Data
Attending to the sociodemographic data (Table 1), the HC
and SUD groups did not differ in age. Nevertheless, although
most of the participants had completed the Spanish compulsory
education (from 6 to 16 years, grades 1–10), the SUD patients had
a lower mean in years of education (p < 0.001). Marital status
showed higher rates of singles in the SUD group compared to
higher rates of married persons in the HC group (p < 0.001), as
well as higher rates of unemployed SUD patients compared to
higher active workers in the HC group (p < 0.001). The age of
OSU and abstinence groups, with no significant age differences
between them, had similar results to those obtained by the SUD
group compared with the HC group. There were differences in
the years of education between theHC and the age of OSU groups
(p < 0.001), as well as in the abstinence groups (p < 0.001). The
post-hoc analyses showed that the OSU ≤ 16 (p < 0.001), SA
(p < 0.001), MA (p = 0.019), and LA (p < 0.001) patients had
fewer years of education than the HC participants. Moreover, the
age of OSU (p < 0.001) and the abstinence (p < 0.001) groups
showed lower rates of married and employed persons (p< 0.001)
than the HC group.
The analyses of the clinical variables indicated significant
differences in the age of the OSU groups, being more frequent
in the OSU ≤ 16 group to have polydrug use (p = 0.014),
residential rather than ambulatory treatment (p = 0.010), and
longer duration of drug use (p < 0.001). Furthermore, the
groups showed differences in the type of substances used. In
the OSU ≤ 16 group, there were higher rates of cannabis
(p = 0.001) and hallucinogens consumption (p = 0.033). In
the total SUD sample, as well as in both groups, the substances
more frequently used were cocaine (88.6%), alcohol (71.1%), and
cannabis (42.1%). No differences between the OSU groups were
found in the other clinical characteristics studied. Regarding the
abstinence groups, higher percentage of relatives with SUD was
found in the MA group (p = 0.026) in contrast with the SA
and LA groups. There were also significant differences in type
of treatment, with a higher frequency of patients in residential
treatment in the SA group with respect to the MA and LA groups
(p< 0.001). Moreover, the CGI showed main effects (p= 0.012),
being the LA group significantly better compared to the SA group
(p = 0.031). There were no statistically significant differences in
the daily consumption of medication in the pharmacologically
treated patients between age of OSU groups or among abstinence
groups (see Table 2). Moreover, the opioid agonists prescription
did not show statistical differences for age of OSU groups (13%
for OSU ≤ 16 and 15.5% for OSU ≥ 17; χ2 = 0.149, p = 0.699)
or abstinence groups (18.4% for SA, 11.8% for MA, and 12.5% for
LA; χ2 = 0.811, p= 0.667).
Circadian Typology and Sleep-Wake
Characteristics
Cronbach’s alpha coefficient of internal reliability for the CSM
was adequate for the total SUD sample studied (0.826). Attending
to the age of OSU groups, the ANCOVA analysis did not
show significant differences in the CSM total score. It is worth
mentioning that we found a high percentage of the morning-
type in the SUD patients, especially in the OSU ≥ 17 group
(70.7%). The MANCOVA analyses for the sleep-wake schedules
(total time spent sleeping, wake-up time, bedtime, presence, and
duration of nap) also did not yield any significant differences.
Similarly, no differences were found in the CSM total score, the
circadian typology and the sleep-wake schedules parameters in
the duration of abstinence groups (Table 3).
In the additional analyses carried out considering the type of
treatment (residential or ambulatory) as an independent variable
no significant differences between groups were found regarding
the CSM scores or sleep-wake schedules (p> 0.193; in all cases).
Distal Skin Temperature
The circadian rhythmic characteristics are shown in Table 4 for
the HC and the SUD groups. The MANCOVA analyses revealed
several significant differences between the HC and SUD groups.
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TABLE 1 | Sociodemographic data for all groups.
HC Total SUD Statistical
(n = 103) (n = 114) contrasts
Age (yrs) 37.68 ± 1.11 35.26 ± 0.71 t = −1.877
Years of education 12.50 ± 0.19 10.28 ± 0.22 U = 1494***
Marital status χ2 = 30.484***
Single 24.6% 53.5%
Separate/Divorced 9.8% 19.20%
Married 44.3% 14.9%
Stable partner 19.7% 12.3%
Economic status χ2 = 103.839***
Active 93.9% 25.4%
Unemployed 1.0% 31.6%
No income 0% 21.1%
Disability pension 5.1% 14.9%
Sick leave 0% 7%
HC OSU ≤ 16 OSU ≥ 17 Statistical HC SA MA LA Statistical
(n = 103) (n = 56) (n = 58) contrasts (n = 103) (n = 38) (n = 35) (n = 41) contrasts
Age (yrs) 37.68 ± 1.11 34.11 ± 1.17 36.40 ± 0.79 F = 1.034 37.68 ± 1.11 34.50 ± 1.21 33.94 ± 1.02 37.10 ± 1.33 F = 0.976
Years of education 12.50 ± 0.19 10.10 ± 0.32 10.47 ± 0.31 F = 23.070*** 12.50 ± 0.19 9.89 ± 0.32 10.58 ± 0.47 9.85 ± 0.33 F = 19.112***
Marital status χ2 = 28.649*** χ2 = 122.075***
Single 24.6% 50% 56.9% 24.6% 57.9% 65.7% 39%
Separate/Divorced 9.8% 21.4% 17.2% 9.8% 26.4% 5.7% 24.4%
Married 44.3% 14.3% 15.5% 44.3% 7.9% 11.4% 24.4%
Stable partner 19.7% 14.3% 10.3% 19.7% 7.9% 17.1% 12.2%
Economic status χ2 = 108.343*** χ2 = 41.789***
Active 93.9% 16.1% 34.5% 93.9% 15.8% 22.9% 36.6%
Unemployed 1.0% 32.1% 31% 1.0% 26.3% 37.1% 31.7%
No income 0% 25% 17.2% 0% 31.6% 14.3% 17.1%
Disability pension 5.1% 19.6% 10.3% 5.1% 18.4% 11.4% 14.6%
Sick leave 0% 7.1% 6.9% 0% 7.9% 14.3% 0%
HC, healthy controls; SUD, substance use disorder; yrs, years; OSU ≤ 16, onset of substance use at age 16 or earlier; OSU ≥ 17, onset of substance use at age 17 or later; SA, short
abstinence; MA, medium abstinence; LA, long abstinence. ***p < 0.001.
SUD patients were characterized by higher values in minimum
temperature (p = 0.012), amplitude (p = 0.001), Rayleigh vector
(p = 0.001), %V (p = 0.001), first harmonic power (p = 0.001)
and accumulated power after 12 harmonics (p = 0.001), IS
(p = 0.001), lower values in the circadianity index (p = 0.001),
and an advanced acrophase (p = 0.019) in contrast to the HC
group.
The distal skin temperature functions for the HC and total
SUD sample are presented in Figure 1. The SUD patients showed
a pattern with higher and more stable values at night, in
comparison to the HC group, as seen in the differences in the
M5 (p= 0.002), and lower and more variable during the day. The
rise in M5 in the SUD patients is related to the higher RA in the
HC (p= 0.002).
The comparisons between the HC and the age of OSU groups
are showed in Table 4. The two age of OSU groups had an
advanced acrophase and higher values in the Rayleigh vector, IS
andM5 than the HC group (p< 0.033, in all cases). The values of
OSU≥ 17 group were higher than the HC and OSU≤ 16 groups
in several cosinor and non-parametric data: amplitude, %V, first
harmonic power and relative amplitude (p < 0.039, in all cases).
The accumulated power after 12 harmonics was higher in the
OSU ≥ 17 group in contrast to the values of HC and OSU ≤ 16
groups (p < 0.029), and also higher in the OSU ≤ 16 group than
in the HC group (p = 0.031). The OSU ≤ 16 group showed
higher values in minimum temperature (p = 0.009) and lower
circadianity index (p = 0.002) with respect to the HC group,
without differences with the OSU ≥ 17 group.
Figure 2 shows the distal skin temperature functions for the
OSU groups. The temperature values during the day (L10) were
higher in the OSU ≤ 16 group, although the contrast with
the OSU ≥ 17 group was not significant. However, there were
significant differences in relative amplitude (p = 0.034), which
was higher in the OSU ≥ 17 group.
On the other hand, significant statistical differences for several
distal skin temperature variables were found between the HC
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TABLE 2 | Clinical data for the whole SUD sample and all their subgroups.
Clinical data Total SUD OSU ≤ 16 OSU ≥ 17 Statistical SA MA LA Statistical
(n = 114) (n = 56) (n = 58) contrasts (n = 38) (n = 35) (n = 41) contrasts
Relatives with SUD 18.4% 23.2% 13.8% χ2 = 1.683 18.4% 31.4% 7.3% χ2 = 7.305*
Relatives with others psychiatric disorder 24.6% 25% 24.1% χ2 = 0.011 31.6% 14.3% 26.8% χ2 = 3.118
Number of suicidal attempts 0.25 ± 0.06 0.29 ± 0.78 0.22 ± 0.56 U = 1616.50 0.29 ± 0.12 0.17 ± 0.57 0.29 ± 0.11 F = 0.376
Consumption pattern
One substance 28.9% 21.4% 36.2% χ2 = 3.025 42.1% 17.1% 26.8% χ2 = 5.659
Two substances 32.5% 28.6% 36.2% χ2 = 0.758 21.1% 37.1% 39% χ2 = 3.412
Polydrug use 38.6% 50% 27.6% χ2 = 6.039* 36.8% 45.7% 34.1% χ2 = 1.140
Substances useda
Cocaine 88.6% 83.9% 93.1% χ2 = 2.374 84.2% 93.4% 87.6% χ2 = 2.101
Alcohol 71.1% 75% 67.2% χ2 = 0.834 57.9% 80% 75.6% χ2 = 4.975
Cannabis 42.1% 57.1% 27.6% χ2 = 10.212*** 36.8% 48.6% 41.5% χ2 = 1.039
Hallucinogens 15.8% 23.2% 8.6% χ2 = 4.564** 15.8% 14.3% 17.1% χ2 = 0.110
Opioids 16.7% 19.6% 13.8% χ2 = 0.702 18.4% 17.1% 14.6% χ2 = 0.212
Sedatives 1.8% 1.8% 1.7% χ2 = 0.001 2.6% 0% 2.4% χ2 = 0.906
Age of OSU (yrs) 18.67 ± 0.49 15.32 ± 0.39 21.90 ± 0.65 U = 73.50** 17.34 ± 0.71 19.71 ± 0.88 19.01 ± 0.92 F = 2.008
Duration of drug use (yrs) 16.35 ± 0.81 18.10 ± 1.18 14.66 ± 1.08 t = 2.162*** 16.74 ± 1.21 14.30 ± 1.42 17.73 ± 1.50 F = 1.567
Typology of treatment regimen χ2 = 6.634* χ2 = 17.021***
Residential 63.2% 75% 51.7% 89.5% 51.4% 48.8%
Ambulatory 36.8% 25% 48.3% 10.5% 48.6% 51.2%
Daily number of medication 0.52 ± 0.08 0.64 ± 0.14 0.40 ± 0.09 U = 1483 0.58 ± 0.17 0.54 ± 0.16 0.44 ± 0.11 F = 0.264
Months of abstinence 8.18 ± 0.45 7.64 ± 0.62 8.69 ± 0.66 U = 1404.50 4.11 ± 0.11 7.11 ± 0.17 13.12 ± 0.73 F = 100.643***
Past treatment for SUD 49% 45.3% 53.2% χ2 = 0.623 53.3% 56.3% 39.5% χ2 = 2.278
Number of previous relapses
None 57% 53.6% 60.3% χ2 = 0.533 52.6% 54.3% 63.4% χ2 = 1.089
One 16.7% 14.3% 19% χ2 = 0.449 15.8% 20% 14.6% χ2 = 0.423
Two 10.5% 14.3% 6.9% χ2 = 1.652 13.2% 11.4% 7.3% χ2 = 0.758
Three or more 15.8% 17.9% 13.8% χ2 = 0.354 18.4% 14.3% 14.6% χ2 = 0.299
DAST-20. Direct Score 12.41 ± 0.46 12.76 ± 0.56 12.03 ± 0.75 t = 0.788 12.41 ± 0.79 12.16 ± 0.78 12.70 ± 0.84 F = 0.114
Addiction severity (DAST-20) χ2 = 0.676 χ2 = 0.813
Low/Intermediate 32.9% 35.1% 30.3% 27.3% 36% 34.8%
Substantial 40.0% 35.1% 45.5% 45.5% 40% 34.8%
Severe 27.1% 29.7% 24.2% 27.3% 24% 30.4%
CGI. Direct Score 2.45 ± 0.11 2.57 ± 0.17 2.33 ± 0.15 U = 1428 2.29 ± 0.20 2.39 ± 0.14 2.80 ± 0.20 F = 4.636*
Daily number of cigarettes 12.50 ± 0.78 12.54 ± 1.11 12.47 ± 1.11 U = 1593 11.82 ± 1.28 11.09 ± 1.26 14.34 ± 1.44 F = 1.654
Daily beverages with caffeine 1.88 ± 0.15 1.86 ± 0.23 1.90 ± 0.20 t = 0.045 1.82 ± 0.29 1.63 ± 0.22 2.15 ± 0.27 F = 0.979
SPAQ. Direct Score 5.76 ± 0.46 6.02 ± 0.70 5.52 ± 0.61 t = 0.541 6.05 ± 0.82 5.60 ± 0.89 5.63 ± 0.72 F = 0.097
Seasonal Affective Disorder (SPAQ) 15% 16.4% 13.8% χ2 = 0.146 13.2% 17.6% 15.1% χ2 = 0.201
SUD, Substance use disorder; OSU ≤ 16, onset of substance use at age 16 or earlier; OSU ≥ 17, onset of substance use at age 17 or later; SA, short abstinence; MA, medium
abstinence; LA, long abstinence; OSU, Onset of Substance Use; yrs, years; DAST-20, Drug Abuse Screening Test; CGI, Clinical Global Impression; SPAQ, Seasonal Pattern Assessment
Questionnaire.
aPercentages will not equal 100 as each participant may take more than one substance of abuse. *p < 0.05, **p < 0.01, ***p < 0.001.
and the abstinence groups (Table 5). The three abstinence groups
were characterized by higher values in the Rayleigh vector
(p < 0.004), accumulated power after 12 harmonics (p < 0.041),
and IS (p < 0.045) in contrast to the HC group. We also found
higher values of the MA and LA groups, compared with the HC
and SA groups, on the amplitude (p < 0.002), first harmonic
power (p < 0.032), and relative amplitude (p < 0.004). The MA
and LA groups showed higher values in the M5 (p < 0.015)
with respect to the HC group. Only the LA group showed
higher values in %V (p < 0.001), in contrast to the HC group.
The SA group presented a more advanced acrophase than the
HC group (p < 0.001), and lower values in TL10 than the
LA group (p < 0.049). Furthermore, the SA and MA groups
showed lower values in the circadianity index (p = 0.017) with
respect to the HC group. Finally, the LA patients had lower
values in minimum temperature (p = 0.041) in contrast to
the SA patients, and lower IV than the SA, and MA patients
(p< 0.047).
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TABLE 3 | Circadian typology and sleep-wake data for the whole SUD sample and all their subgroups.
Circadian typology and Total SUD OSU ≤ 16 OSU ≥ 17 Statistical SA MA LA Statistical
sleep-wake data (n = 114) (n = 56) (n = 58) contrasts (n = 38) (n = 35) (n = 41) contrasts
CSM. Direct Score 37.96 ± 6.57 36.81 ± 6.79 39.02 ± 6.22 F = 2.702 38.03 ± 6.17 37.89 ± 6.38 38.13 ± 7.20 F = 0.012
Circadian typology (CSM) χ2 = 2.386 χ2 = 1.301
Morning-type 64.3% 57.4% 70.7% 62.2% 65.7% 65%
Neither-type 30.4% 35.2% 25.9% 35.1% 28.6% 27.5%
Evening-type 5.4% 7.4% 3.4% 2.7% 5.7% 7.5%
Total time spent sleeping (hrs) 8.01 ± 0.91 8.09 ± 0.91 7.92 ± 0.84 F = 0.790 8.07 ± 0.99 8.13 ± 0.70 7.87 ± 0.90 F = 0.912
Wake-up timea 06:53 ± 01:42 06:39 ± 02:08 07:07 ± 01:07 F = 1.073 06:33 ± 01:32 07:18 ± 01:29 06:52 ± 02:16 F = 1.208
Bedtimea 23:20 ± 01:17 23:12± 01:38 23:28 ± 00:59 F = 1.405 23:22 ± 01:15 23:26 ± 00:57 23:14 ± 1:42 F = 0.302
Nap duration (min) 18.09 ± 30.58 20.19 ± 35.97 16.14 ± 24.69 F = 0.459 20.14 ± 30.02 17.21 ± 34.26 19.02 ± 23.09 F = 0.038
Presence of nap 30.4% 35.2% 25.9% χ2 = 0.221 31.6% 34.3% 31.7% χ2 = 0.077
SUD, Substance use disorder; OSU ≤ 16, onset of substance use at age 16 or earlier; OSU ≥ 17, onset of substance use at age 17 or later; SA, short abstinence; MA, medium
abstinence; LA, long abstinence; CSM, Composite Scale of Morningness; hrs, hours; min, minutes.
aData are expressed in hours and minutes.
Figure 3 shows the distal skin temperature functions for the
abstinence groups. There is a tendency to obtain higher values in
the M5 and lower values in the L10 as the duration of abstinence
increases. This is based in the significant differences found in
the RA between the SA and LA groups. Moreover, there is also
a phase delay in the TL10 and TM5 as the duration of abstinence
increases.
In the additional analyses performed considering the type of
treatment (residential or ambulatory) only a significant difference
was found in acrophase [F(1, 112)= 7.223; p= 0.008; η
2
p= 0.061],
being advanced in the ambulatory group.
DISCUSSION
This study intended to clarify, for the first time, the possible
existence of clinical and circadian (sleep-wake schedules,
circadian typology, and distal skin temperature) differences in
men with SUD under treatment after detox, depending on the
age of OSU and the duration of abstinence. Furthermore, we
also explored differences in the circadian rhythm of distal skin
temperature between SUD patients and HC participants.
The SUD patients showed a less adaptive sociodemographic
pattern than the HC group, with fewer years of education, a
greater tendency to remain single and unemployed, consistent
with the epidemiological data available on SUD patients (1, 2, 72).
This is so regardless of the age of OSU and the duration of
abstinence. Given the high impact of the SUD on the functioning
of the individuals affected, the data reinforce the need to continue
the research on how to improve their prevention and treatment
programs.
Both in the total SUD sample and in all the groups of
participants, the substances more frequently consumed were
cocaine, alcohol, and cannabis, in accordance with both the world
and the Spanish data on main substances of clinical diagnosis
(2, 72). However, the patients in the OSU≤ 16 group had a higher
frequency of cannabis and hallucinogens consumption than the
OSU ≥ 17 group. This may reflect the tendency to use certain
substances linked to the life period of onset of consumption
(72). Both in the OSU ≤ 16 group and in the SA there is a
higher number of patients who need a more intensive treatment
(residential) to achieve abstinence compared to the OSU ≥ 17
and MA/LA groups, respectively. These residential programs,
in contrast with the ambulatory ones, are addressed to those
patients who are experiencing severe drug-related problems (73).
In this sense, the OSU ≤ 16 patients presented greater duration
of drug use and consumption of more substances, both factors
being related to the severity of the addiction (74). These results
highlight the evidence that an early age of OSU is related to a
more severe clinical symptomatology in adult age (4–6), and are
in accordance with the works that use the same cut-off point
(7, 8). The better clinical impression of the LA patients compared
to the SA group supports the progressive symptomatic recovery
as the duration of abstinence increases (75).
Attending to their sleep-wake schedules, there were more
morning-type patients in the SUD group, with respect to
the normative Spanish data (67). There were no significant
differences between the OSU and abstinence groups, and this
was more evident in the OSU ≥ 17 group. This tendency to a
morning-type was also seen in the advancement of the acrophase
of the SUD patients with respect to the HC group. Moreover,
the analyses of the parameters of distal skin temperature
indicated that, globally, the SUD patients presented a better
circadian functioning (higher amplitude, Rayleigh vector, %V,
first harmonic power, accumulated power after 12 harmonics, IS,
RA, and M5) compared to the HC. These data differ from those
reported in previous studies linking eveningness with substance
use (37, 40) and those suggesting that circadian rhythmic
alteration produced by consumption may last for months after
the onset of the abstinence (27–31). This may be explained by the
methodological differences, especially by the longer minimum
abstinence time (3 months) of the patients in our sample, and
also because they do not present active consumption (confirmed
by urinalysis), as was also done in Antúnez et al. (76) with
SUD patients and with results similar to ours. The therapeutic
approach in SUD patients establishes patterns of sleep-wake
and regular daily activities in tune with the solar cycle of
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TABLE 4 | Distal skin rhythmic variables for the HC, SUD and age of OSU groups.
HC Total SUD F η2p HC OSU ≤ 16 OSU ≥ 17 F η
2
p Significant
(n = 103) (n = 114) (n = 103) (n = 56) (n = 58) contrasts
COSINOR DATA
Maximum temp 36.07 ± 0.46 36.11 ± 0.59 0.280 36.07 ± 0.46 36.02 ± 0.56 36.19 ± 0.61 1.484
Minimum temp 30.39 ± 1.66 30.87 ± 1.68 6.430* 0.029 30.39 ± 1.66 31.12 ± 1.52 30.63 ± 1.79 5.671** 0.054 HC < OSU≤16
Mesor 33.60 ± 0.63 33.63 ± 0.86 0.192 33.60 ± 0.63 33.71 ± 0.86 33.55 ± 0.87 1.291
Amplitude 0.79 ± 0.44 1.07 ± 0.71 10.844** 0.048 0.79 ± 0.44 0.87 ± 0.58 1.26 ± 0.77 11.001*** 0.099 HC, OSU ≤ 16
< OSU ≥ 17
Acrophasea 02:06 ± 01:39 00:41 ± 03:17 11.886** 0.053 02:06 ± 01:39 00:48 ± 03:09 00:35 ± 03:25 5.097** 0.048 OSU ≤ 16, OSU
≥ 17 < HC
Rayleigh vector 0.75 ± 0.18 0.91 ± 0.19 35.155*** 0.175 0.75 ± 0.18 0.89 ± 0.20 0.92 ± 0.19 18.981*** 0.160 HC < OSU ≤
16, OSU ≥ 17
%V 18.16 ± 11.35 26.63 ± 18.02 17.416*** 0.078 18.16 ± 11.35 23.09 ± 16.22 29.90 ± 19.12 11.424*** 0.103 HC, OSU ≤ 16
< OSU ≥ 17
1st HP 0.40 ± 0.42 0.79 ± 1.04 11.849** 0.053 0.40 ± 0.42 0.55 ± 0.75 1.03 ± 1.23 11.839*** 0.106 HC, OSU ≤ 16
< OSU ≥ 17
12th HAP 0.69 ± 0.62 1.60 ± 1.61 27.165*** 0.113 0.69 ± 0.62 1.29 ± 1.46 1.90 ± 1.70 17.048*** 0.146 HC < OSU ≤ 16
< OSU ≥ 17
Circadianity
index
50.60 ± 20.58 42.12 ± 21.85 8.014** 0.036 50.60 ± 20.58 37.87 ± 21.50 46.24 ± 21.81 6.212** 0.055 OSU ≤ 16 < HC
NON-PARAMETRIC DATA
Interdaily
Stability (IS)
0.40 ± 0.15 0.75 ± 0.16 26.407*** 0.552 0.40 ± 0.15 0.72 ± 0.15 0.77 ± 0.17 20.364*** 0.256 HC < OSU ≤
16, OSU ≥ 17
Intradaily
Variability (IV)
0.23 ± 0.10 0.24 ± 0.10 0.215 0.23 ± 0.10 0.26 ± 0.17 0.22 ± 0.11 1.984
Relative
Amplitude (RA)
0.02 ± 0.01 0.03 ± 0.02 9.635** 0.043 0.02 ± 0.01 0.03 ± 0.02 0.04 ± 0.02 9.497*** 0.087 HC, OSU≤16 <
OSU ≥ 17
MD temp 34.41 ± 0.58 34.47 ± 0.72 3.642 34.41 ± 0.58 34.46 ± 0.63 34.49 ± 0.80 1.829
ASP temp 33.10 ± 0.94 32.92 ± 1.29 1.321 33.10 ± 0.94 33.03 ± 1.35 32.82 ± 1.22 1.148
ED temp 33.48 ± 1.09 33.46 ± 1.31 0.003 33.48 ± 1.09 33.69 ± 1.19 33.24 ± 1.38 2.228
NP temp 33.28 ± 1.02 33.26 ± 1.34 0.033 33.28 ± 1.02 33.35 ± 1.35 33.17 ± 1.32 0.606
M5 34.58 ± 0.49 34.88 ± 0.84 9.690** 0.043 34.58 ± 0.49 34.90 ± 0.82 34.86 ± 0.87 6.464** 0.061 HC < OSU≤16,
OSU ≥ 17
TM5a 02:39 ± 02:08 01:51 ± 03:01 3.523 02:39 ± 02:08 01:47 ± 02:12 01:55 ± 02:53 1.530
L2 31.99 ± 1.31 31.64 ± 1.79 2.024 31.99 ± 1.31 31.89 ± 1.67 31.40 ± 1.88 2.669
TL2a 20:20 ± 05:21 20:52 ± 06:16 0.140 20:20 ± 05:21 21:33 ± 05:18 20:14 ± 06:59 0.322
L10 32.99 ± 0.86 32.85 ± 1.29 0.663 32.99 ± 0.86 33.06 ± 1.21 32.65 ± 1.34 3.122
TL10a 14:02 ± 03:19 13:15 ± 02:59 3.603 14:02 ± 03:19 13:16 ± 02:35 13:14 ± 03:23 1.523
HC, healthy controls; SUD, Substance use disorder; OSU, onset of substance use; η2p, partial eta square; OSU ≤ 16, onset of substance use at age 16 or earlier; OSU ≥ 17, onset of
substance use at age 17 or later temp temperature; %V, percentage of variance explained by the cosine wave; HP, harmonic power; HAP, harmonic accumulated power; MD, morning
decrease; ASP, afternoon secondary peak; ED, evening decrease; NP, night plateau; M5, maximum mean temperature in 5 consecutive hours; TM5, time when the maximum mean
temperature in 5 consecutive hours was reached; L2, minimum mean temperature in 2 consecutive hours; TL2, time when the minimum temperature in 2 consecutive hours was
reached; L10, minimum mean temperature in 10 consecutive hours; TL10, time when the minimum temperature in 10 consecutive hours was reached.
aData are expressed in hours and minutes. *p < 0.05, **p < 0.01, ***p < 0.001.
light-darkness or the morning typology (73), which is considered
a protection factor against substance consumption (30, 37). Thus,
the patients’ correct rhythmic expression could be considered a
marker of adherence to treatment and of relapse prevention.
However, some temperature parameters suggest only a partial
restitution of the circadian impairment associated to substance
consumption. The SUD patients presented high values in
minimum temperature, indicative of lower activation and more
daytime sleepiness (18, 25), as well as a lower circadianity index
or power of the first harmonic, which has been related to an
immature circadian system (23). Studying the age of OSU and
abstinence groups has contributed to shed light on this issue,
showing that this is found only in those patients with lower
age of OSU (OSU ≤ 16) and shorter duration of abstinence
(SA). Our results indicate that circadian rhythmicity in the SUD
group was better when the period of abstinence was longer. The
LA group showed higher amplitude, first harmonic power and
RA, lower minimum temperature and IV, and delayed TL10
than the SA group, with even better characteristics than the
HC group. However, longitudinal works are required that assess
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FIGURE 1 | Distal skin temperature mean daily patterns for substance use
disorder patients (SUD; continuous line, n: 114) and healthy controls (HC;
dotted line, n = 103). All data are expressed as mean ± standard error of the
mean.
the rhythmicity of patients in the long term, once they have
completed their treatment.
When the cut-off age of OSU was considered we observed
that the OSU ≥ 17 group presented a better circadian distal
skin temperature, characterized by higher amplitude, %V, first
harmonic power, accumulated power after 12 harmonics and RA.
Two hypotheses might explain this observation. First, keeping
in mind the implication of the circadian genes in developing
an addiction (34, 35), it is possible that the OSU ≤ 16 patients
present certain endogenous characteristics previous to the onset
of consumption that, added to a worse synchronization of
environmental rhythms, could make them more vulnerable
to an early onset of substance consumption (77). In this
respect, during adolescence an extreme evening-type pattern
and the presence of social jet-lag are vulnerability factors for
the development of different disorders, including SUD (36,
44). Second, neurotoxicity could underlie the more marked
difficulty in restoring the patients’ rhythmic expression in spite of
following the prescribed treatment. The cut-off age used, based
on neurodevelopmental characteristics, discriminates the early
phase of maturation of the dopaminergic and endocannabinoid
systems (36, 54). Dopamine is the main neuromodulator of the
reward system and is involved in the regulation of the clock genes
and the circadian rhythms (36, 55). Thus, it is possible that the
early consumption of substances affects the correct development
of both systems with dysfunctions more perdurable than those
produced by a later age of OSU. Unfortunately, the design of our
study does not allow us to clarify these issues at the moment.
In this way, the OSU ≤ 16 patients are established as a risk
group with a smaller response to interventions, a more severe
clinical presentation and greater difficulty in recovering circadian
rhythmicity, in comparison with the OSU ≥ 17 patients. Given
that a good circadian functioning has been related to better
health (9, 10), greater quality of life (49) and better work
and academic adjustment (40, 47), these type of patients could
benefit from more intense chronobiological strategies, such as
FIGURE 2 | Distal skin temperature mean daily patterns for substance use
disorders according to the age of Onset of Substance Use (OSU). Continuous
line represents OSU ≥ 17 (n = 58) and dotted line OSU ≤ 16 (n = 56). All data
are expressed as mean ± standard error of the mean.
the administration of exogenousmelatonin, or light-therapy (37).
Moreover, since the OSU ≤ 16 patients could have a lower
cognitive performance (7, 50–52) and cognitive functions show
circadian rhythmicity (13, 15), it could work in favor of their
recovery to program more demanding cognitive interventions
(such as the cognitive-behavioral) for the time frames when they
present more optimal levels of activity.
Our study also has some limitations. A great number of the
patients in our sample were polyconsumers, and this made it
impossible to tell apart the possible differential effects of each
substance on the circadian characteristics, although in our study
their effect is relatively under control, since the same main
substances had been consumed in the groups. The fact that
our sample only consists of men eliminates the influence of
gender-related variables, but on the other hand it limits the
generalization of the results. The wide range of age in the sample
may have also contributed to a type-II error. Moreover, we
have not recorded the activity-rest nor the exposition to light,
which would have allowed for a more integrated and complete
assessment of circadian rhythmicity (20, 78), nor the content and
schedule of food/drink intake that may interfere in the rhythm
of temperature (11). Finally, we have analyzed cross-sectional
data, which does not allow establishing causal relations between
variables.
CONCLUSIONS
Our results may have clinical implications. The alterations in
the distal skin temperature (a good marker of the circadian
system) associated to the SUD may be restored, this being
influenced by the duration of abstinence and the age of OSU.
Thus, the circadian functioning improves as the time without
consumption increases, and this can be considered as an
indicator of good adherence and response to treatment (with
almost no interference from its modality). In this sense, the
distal skin temperature rhythm could be used as a reliable and
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TABLE 5 | Distal skin circadian rhythmic variables for the HC and duration of abstinence groups.
HC SA MA LA F η2p Significant
(n = 103) (n = 38) (n = 35) (n = 41) contrasts
COSINOR DATA
Maximum temp 36.07 ± 0.46 36.07 ± 0.58 36.07 ± 0.56 36.20 ± 0.67 0.590
Minimum temp 30.39 ± 1.66 31.30 ± 1.42 30.97 ± 1.84 30.43 ± 1.57 4.934** 0.069 LA, HC < SA
Mesor 33.60 ± 0.63 33.79 ± 0.84 33.70 ± 0.94 33.49 ± 0.77 1.471
Amplitude 0.79 ± 0.44 0.84 ± 0.68 1.06 ± 0.68 1.33 ± 0.69 8.290*** 0.111 HC, SA < LA
Acrophasea 02 : 06 ± 01 : 39 23 :47 ± 04 : 02 01 :23 ± 03 :21 01 : 24 ± 04 :16 6.047** 0.084 SA < HC
Rayleigh vector 0.75 ± 0.18 0.86 ± 0.25 0.91 ± 0.18 0.93 ± 0.15 13.093*** 0.165 HC < SA, MA, LA
%V 18.16 ± 11.35 22.74 ± 17.82 25.72 ± 18.60 31.84 ± 17.42 7.748*** 0.105 HC < LA
1st HP 0.40 ± 0.42 0.58 ± 1.12 0.78 ± 0.91 1.11 ± 1.11 7.211*** 0.098 HC, SA < LA
12th HAP 0.69 ± 0.62 1.19 ± 1.44 1.57 ± 1.45 2.03 ± 1.77 12.730*** 0.161 HC < SA, MA, LA
Circadianity index 50.60 ± 20.58 38.60 ± 22.95 37.85 ± 21.79 49.30 ± 19.35 5.137** 0.068 SA, MA < HC
NON-PARAMETRIC DATA
Interdaily Stability (IS) 0.40 ± 0.15 0.70 ± 0.19 0.75 ± 0.16 0.75 ± 0.13 28.121*** 0.541 HC < SA, MA, LA
Intradaily Variability (IV) 0.23 ± 0.10 0.26 ± 0.13 0.29 ± 0.19 0.18 ± 0.8 3.420* 0.049 LA < SA, MA
Relative Amplitude (RA) 0.02 ± 0.01 0.03 ± 0.02 0.03 ± 0.02 0.04 ± 0.02 7.909*** 0.107 HC, SA < LA
MD temp 34.41 ± 0.58 34.44 ± 0.75 34.51 ± 0.74 34.48 ± 0.69 1.280
ASP temp 33.10 ± 0.94 33.05 ± 1.32 32.96 ± 1.38 32.77 ± 1.19 0.853
ED temp 33.48 ± 1.09 33.77 ± 1.21 33.49 ± 1.42 33.15 ± 1.25 1.948
NP temp 33.28 ± 1.02 33.58 ± 1.05 33.08 ± 1.62 33.10 ± 1.28 1.677
M5 34.58 ± 0.49 34.70 ± 0.96 35.02 ± 0.54 35.09 ± 0.89 6.507*** 0.089 HC < MA, LA
TM5a 02 : 39 ± 02 : 08 01 :09 ± 03 : 00 02 :04 ± 03 :51 02 : 39 ± 03 :22 2.436
L2 31.99 ± 1.31 32.03 ± 1.63 31.46 ± 2.23 31.42 ± 1.46 2.010
TL2a 20 : 20 ± 05 : 21 22 :12 ± 06 : 26 20 :03 ± 05 :49 20 : 13 ± 06 :01 0.529
L10 32.99 ± 0.86 33.10 ± 1.14 32.90 ± 1.28 32.53 ± 1.24 2.249
TL10a 14 : 02 ± 03 : 19 12 :46 ± 04 : 26 13 :20 ± 02 :03 14 : 26 ± 03 :54 2.728* 0.040 SA < LA
HC, healthy controls; SA, short abstinence; MA, medium abstinence; LA, long abstinence; η2p, partial eta square; temp, temperature; %V, percentage of variance explained by the cosine
wave; HP, harmonic power; HAP, harmonic accumulated power; MD, morning decrease; ASP, afternoon secondary peak; ED, evening decrease; NP, night plateau; M5, maximum mean
temperature in 5 consecutive hours; TM5, time when the maximum mean temperature in 5 consecutive hours was reached; L2, minimum mean temperature in 2 consecutive hours;
TL2, time when the minimum temperature in 2 consecutive hours was reached; L10, minimum mean temperature in 10 consecutive hours; TL10, time when the minimum temperature
in 10 consecutive hours was reached.
aData are expressed in hours and minutes. *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 3 | Distal skin temperature mean daily patterns for duration of
abstinence. Continuous line represents short abstinence (SA, n = 38), dotted
line medium abstinence (MA, n = 35) and discontinued line long abstinence
(LA, n = 41). All data are expressed as mean ± standard error of the mean.
simple procedure to monitor the patients’ response to treatment.
Given the relationship between health and circadian rhythms, it
would be advisable to do post-intervention follow-ups in order
to ensure that the results are maintained. On the other hand,
although the age of OSU groups presents similar periods of
abstinence and hygienic habits of sleep-wake in the morning-
type, the OSU ≤ 16 group appears as the more vulnerable with
patients may require from more complex interventions in which
it would be beneficial to emphasize the rhythmic aspects. Finally,
it would be interesting to include chronobiological assessments
in the SUD prevention programs, as well as to boost those
chronotherapies addressed to adolescents.
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